CONSOLIDATED STATEMENTS OF INCOME (LOSS) (USD $) In Millions, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues
Product sales	$ 2,022.9	$ 1,506.4	$ 5,868.1	$ 3,608.8
Other revenues	33.3	35.3	115.4	97.0
Total revenues	2,056.2	1,541.7	5,983.5	3,705.8
Expenses
Cost of goods sold (exclusive of amortization and impairments of finite-lived intangible assets shown separately below)	545.8	560.8	1,619.5	1,128.9
Cost of other revenues	15.0	14.4	45.3	44.3
Selling, general and administrative	504.1	355.7	1,501.8	854.9
Research and development	59.1	49.0	186.9	97.3
Amortization and impairments of finite-lived intangible assets (see Note 9)	393.1	910.2	1,113.9	1,540.0
Restructuring, integration and other costs	61.7	243.1	337.4	345.7
In-process research and development impairments and other charges	19.9	124.0	40.3	128.8
Acquisition-related costs	1.6	8.6	3.7	24.4
Acquisition-related contingent consideration	4.0	(35.0)	14.8	(33.5)
Other (income) expense	(232.0)	202.4	(275.7)	208.0
Total expenses	1,372.3	2,433.2	4,587.9	4,338.8
Operating income (loss)	683.9	(891.5)	1,395.6	(633.0)
Interest income	0.8	2.8	3.8	5.4
Interest expense	(258.4)	(249.3)	(746.1)	(581.4)
Loss on extinguishment of debt	0	(8.2)	(93.7)	(29.6)
Foreign exchange and other	(53.0)	5.1	(63.0)	(3.5)
Gain on investments, net	3.4	0	5.9	5.8
Income (loss) before provision for (recovery of) income taxes	376.7	(1,141.1)	502.5	(1,236.3)
Provision for (recovery of) income taxes	100.3	(169.2)	124.4	(247.7)
Net income (loss)	276.4	(971.9)	378.1	(988.6)
Less: Net income (loss) attributable to noncontrolling interest	1.0	1.3	(0.5)	1.3
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	$ 275.4	$ (973.2)	$ 378.6	$ (989.9)
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic (in dollars per share)	$ 0.82	$ (2.92)	$ 1.13	$ (3.13)
Diluted (in dollars per share)	$ 0.81	$ (2.92)	$ 1.11	$ (3.13)
Weighted-average common shares
Basic (in shares)	335.4	333.6	335.2	316.5
Diluted (in shares)	341.3	333.6	341.4	316.5